RAPT NASDAQ
RAPT Therapeutics, Inc.
1W: +0.1%
1M: +0.4%
3M: +80.8%
YTD: +82.1%
1Y: +541.7%
3Y: -75.7%
5Y: -61.3%
$58.01
Last traded 2026-03-06 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-12-23
Earliest Filing
2026-03-03
Latest Filing
acquirer: 5
partner: 2
Counterparties (Filed by RAPT)
7 relationshipsCompanies named in RAPT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| GlaxoSmithKline LLC | — | acquirer | Parent company of Purchaser that acquired RAPT Therapeutics, Inc. via a merger. | 2026-03-03 | View |
| Redrose Acquisition Co. | — | acquirer | Wholly owned subsidiary of GlaxoSmithKline LLC that acquired RAPT Therapeutics, Inc. via a merger. | 2026-03-03 | View |
| The Nasdaq Stock Market LLC | — | partner | Exchange where RAPT Therapeutics, Inc. shares were listed prior to delisting following the merger. | 2026-03-03 | View |
| GlaxoSmithKline LLC | — | acquirer | Parent company entering into a merger agreement to acquire RAPT Therapeutics, Inc. | 2026-01-20 | View |
| Redrose Acquisition Co. | — | acquirer | Wholly owned subsidiary of GlaxoSmithKline LLC acting as the Purchaser in the merger. | 2026-01-20 | View |
| GSK plc | GLAXF | acquirer | Ultimate parent company providing a guaranty for the merger agreement. | 2026-01-20 | View |
| Shanghai Jemincare Pharmaceutical Co., Ltd. | — | partner | Licensed anti-IgE monoclonal antibody JYB1904 to RAPT Therapeutics, Inc. for global development and commercialization ou | 2024-12-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-03-03 | Completion of Acquisition or Disposition of Assets; Notice of Delisting or Transfer; Material Modifi | Acquisition | View |
| 2026-01-20 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-28 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-23 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-17 | Amendments to Articles of Incorporation or Bylaws | View | |
| 2025-06-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-29 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-28 | Notice of Delisting or Transfer | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-01-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-23 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR